Загрузка...

Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer

The objectives of this study were to characterize the pharmacokinetics (PK) of LY2510924, a potent peptide antagonist of the CXCR4 receptor, after subcutaneous administration in patients with advanced cancer forms and quantify LY2510924 stimulatory effects on the mobilization of cells bearing the cl...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :CPT Pharmacometrics Syst Pharmacol
Главные авторы: Bihorel, S, Raddad, E, Fiedler‐Kelly, J, Stille, JR, Hing, J, Ludwig, E
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2017
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5613202/
https://ncbi.nlm.nih.gov/pubmed/28643374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12221
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!